



# 4CPS-122 - OVERVIEW OF THE IMPACT OF PENICILLIN ALLERGY LABELS ON ANTIBIOTIC USE IN THE EMERGENCY DEPARTMENT

<u>G. Garreta<sup>1</sup>, N. Meca, C. Sebastián, M. Iglesias, F. Salazar, J. Pardo, J. Nicolas<sup>1</sup>.</u> <sup>1</sup>H. U. Mutua De Terrassa, Pharmacy, Terrassa, Spain.

Many patients claim to be allergic to penicillin (Pen-A), however only 10-25% of these are truly penicillin allergic. It needs to be established if they are truly allergic (type-1 allergy) in order to to indicate alternative antibiotics. Moreover, patients who do not have a type-1 allergy can safely receive cephalosporins or carbapenems, but having a label of Pen-A may be associated with prescription of broad spectrum antibiotics (BSA), hospital stay duration and readmission.

## Aim and objectives

**Background and importance** 

• Assess the impact of Pen-A labels on antibiotic in emergency department (ED)

- Identify patients who remain appropriate candidates to receive beta-lactam therapy or cephalosporins, are mislabeled or may be dislabeled with **Penicillin allergy skin testing (PST)**.

### Material and methods

Retrospective-cohort study with ED cases treated with BSA from january 2020-2021.



Pen-A were identified by assessing all allergies in the electronic medical record.


Each patient with a Pen-A label was matched for: age, gender, BSA prescribed in ED and previous exposures to penicillin or cephalosporins.

**PST** may be considered if they meet any of the criteria recommended:

- History of Pen-A > 10 years ago
- Frequent antibiotic use required
- Immunosuppressed-state
- History of infections caused by multidrug-resistant (MDR) bacteria

#### Results

A total of 287 patients (mean age=62 years; SD=16 years; 53% men) were enrolled.



nospital guides suggested	
treatments with a	
cephalosporin.	

## Conclusions

- Most patients, around 80% would have been spared the use of BSA if the Pen-A label had been assessed.  $\mathbf{V}$
- Furthermore, most patients who had received cephalosporins did not have cross-reactivity.  $\checkmark$
- The introduction of PST could help correctly verify Pen-A in 65,2% patients.  $\checkmark$
- Hereinafter, ED-pharmacist will be prepared to evaluate possible Pen-A to reduce the use of BSA and de-label when necessary.  $\checkmark$